Williamson DB, Sohn CJ, Ito A, Haltiwanger RS. POGLUT2 and POGLUT3 O-glucosylate multiple EGF repeats in fibrillin-1, -2, and LTBP1 and promote secretion of fibrillin-1. J Biol Chem. 2021 Sep;297(3):101055. doi: 10.1016/j.jbc.2021.101055
Furze CM, Delso I, Casal E, Guy CS, Seddon C, Brown CM, Parker HL, Radhakrishnan A, Pacheco-Gomez R, Stansfeld PJ, Angulo J, Cameron AD, Fullam E. Structural basis of trehalose recognition by the mycobacterial LpqY-SugABC transporter. J Biol Chem. 2021 Jan;296:100307. doi: 10.1016/j.jbc.2021.100307
Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Davis AE, Mehrotra S, Kilambi V, Kang J, McElroy L, Lapin B, Holl J, Abecassis M, Friedewald JJ, Ladner DP. The effects of the statewide sharing variance on geographic disparity in kidney transplantation in the United States. Clin J Am Soc Nephrol. 2014 Aug 7;9(8):1149-60.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
Hoogeveen EK, Halbesma N, Rothman KJ, Stijnen T, van Dijk S, Dekker FW, Boeschoten EW, de Mutsert R. Obesity and mortality risk among younger dialysis patients. Clin J Am Soc Nephrol. 2012 Feb 1;7(2):280-8.
Layton JB, Hogan SL, Jennette CE, Kenderes B, Krisher J, Jennette JC, McClellan WM. Discrepancy between Medical Evidence Form 2728 and renal biopsy for glomerular diseases. Clin J Am Soc Nephrol. 2010 Nov;5(11):2046-52. doi: 10.2215/CJN.03550410.
Wang OH, Kilpatrick RD, Critchlow CW, Ling X, Bradbury BD, Gilbertson DT, Collins AJ, Rothman KJ, Acquavella JF. Relationship between epoetin alfa dose and mortality: findings from a marginal structural model. Clin J Am Soc Nephrol. 2010 Feb 1;5(2):182-8.
Danese MD, Belozeroff V, Smirnakis K, Rothman KJ. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol. 2008 Sep 1;3(5):1423-9.
Bradbury BD, Fissell RB, Albert JM, Anthony MS, Critchlow CW, Pisoni RL, Port FK, Gillespie BW. Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin J Am Soc Nephrol. 2007 Jan;2(1):89-99.
Vallano A, Mendoza G, Rodríguez A, Rebordosa C. Seguridad de los analgesicos y de los antiinflamatorios. Farm Hosp. 2004;157:23-31.
Kurz EU, Leader KB, Kroll DJ, Clark M, Gieseler F. Modulation of human DNA topoisomerase IIalpha function by interaction with 14-3-3epsilon. J Biol Chem. 2000 May 5;275(18):13948-54.